Skin News and Research

RSS

Cempra Pharmaceuticals announces schedule of poster presentations at ECCMID 2010

Cempra Pharmaceuticals today announced its schedule of poster presentations at the 20th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna, Austria, on April 10-13, 2010.

8 Apr 2010

Parents lack understanding of causes, signs and symptoms of dehydration in children

Dehydration is a condition that can have a significant impact on children and, if left untreated, may lead to serious complications and hospitalization. A national survey of more than 800 parents with children between the ages of one month and 10 years found that three out of five parents reported needing to know more information about dehydration, such as when to see a physician, warning signs, and treatment, if their child became sick - pointing to a greater need for awareness and education around the condition and its treatment.

From Baxter International Inc. 8 Apr 2010

FDA warns false, misleading statements over "lipodissolve" drugs

The U.S. Food and Drug Administration today issued warning letters to six U.S. based medical spas and a company in Brazil for making false or misleading statements on their Web sites about drugs they claim will eliminate fat in a procedure called "lipodissolve," or for otherwise misbranding lipodissolve products.

8 Apr 2010

Cepheid to launch GeneXpert Infinity-48 in Europe at 20th ECCMID

Cepheid will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.

7 Apr 2010

DNA barcoding-sequencing of gene in sand flies identifies two species carrying Leishmania naiffi

In the first survey of sand flies in Panama to use genetic barcoding, scientists at the Smithsonian Tropical Research Institute and Gorgas Memorial Laboratories identified 20 sand fly species from Barro Colorado Island. Two species carried Leishmania naiffi, a parasite that causes cutaneous leishmaniasis: persistent, itchy skin lesions. Three species carried Wolbachia, a bacterial parasite of insects that could contribute to a strategy to control the flies and limit disease transmission.

7 Apr 2010

AHRQ: Women accounted for nearly 60% of 39.4M admissions to U.S. hospitals in 2007

Women accounted for nearly 60 percent of the 39.4 million admissions to U.S. hospitals in 2007, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

7 Apr 2010

IZI Medical Products introduces Mammography Indicator Markers

IZI Medical Products today announced that the company has developed and begun distributing two new lines of flat mammography markers, which are being manufactured in the United States and sold worldwide under the brand, Mammography Indicator® Markers.

7 Apr 2010

Hospital charges for uninsured inpatient care grows by 88%

The amount that hospitals charge the uninsured for inpatient care grew by 88 percent between 1998 and 2007, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. The average charge for an uninsured hospital stay grew from $11,400 in 1998 to $21,400 in 2007 after adjusting for inflation.

7 Apr 2010

Nationwide Phase III clinical trial of OncoVEX for advanced melanoma

Rush University Medical Center is leading a nationwide Phase III clinical trial to determine whether a promising vaccine for advanced melanoma can effectively treat the deadly skin cancer.

7 Apr 2010

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.

7 Apr 2010

Stem cell-enriched autologous fat for breast augmentation

Whereas US and European medical centers are still beginners in breast augmentation with stem cell-enriched autologous fat, Viennese New Cosmetic Surgery and anti-aging expert DDr. Karl-Georg Heinrich is well-versed in this revolutionary method. In his Clinic DDr. Heinrich, he has been successfully offering breast augmentations with autologous stem cells to a broad public since early 2007.

7 Apr 2010

New extra potent sunscreens in the pipeline

Sunscreens are touted to protect your skin from the harmful ultraviolet rays of the sun. However scientists are now studying whether a good sunscreen protects your skin even after your skin is no longer exposed to the sun? This study is undertaken because of the alarming rise in malignant melanoma, a form of skin cancer that is linked to the sun’s UV rays. Malignant melanoma is the most common cancer in Australia and Queensland tops all other places in the world when it comes to incidence of this skin cancer.

7 Apr 2010

Lumenis' 2009 revenues down 12% to $226.1M

Lumenis Ltd., a global leader in developing, manufacturing and distributing a broad range of high-end medical lasers and sophisticated energy delivery equipment for surgical, ophthalmic and aesthetic applications, today announced its financial results for the year ended December 31, 2009 and that it has filed its 2009 annual report on Form 20-F with the U.S. Securities and Exchange Commission.

From Lumenis Inc. 7 Apr 2010

IPS examines malnutrition, obesity in Latin America

Inter Press Service examines malnutrition and factors contributing to the rising rates of "obesity and obesity-related illness - such as type II diabetes, high blood pressure, heart disease, some forms of cancer and osteoporosis - in Latin America, and especially among the poorest sectors of the population."

7 Apr 2010

IGRAs effective for detecting confirmed active TB disease: CHEST

New data from a meta-analysis of existing literature published today in CHEST, the official journal of the American College of Chest Physicians, demonstrate that Interferon Gamma Release Assays are superior to the previous standard in diagnostics, the 100+-year-old tuberculin skin test, for detecting confirmed active Tuberculosis disease.

7 Apr 2010

Astrogenetix narrows in on MRSA virulence onboard space shuttle Discovery

Astronauts on board Space Shuttle Discovery (STS-131) activated an experiment this morning as part of the ninth scientific payload for Astrogenetix, an Austin, Texas-based commercial biotech company. Astrogenetix is conducting the International Space Station National Laboratory Pathfinder Vaccine (NLP-V) missions to take advantage of the unique conditions of microgravity to uncover changes in bacteria that can be targeted to create new vaccines and therapeutics.

6 Apr 2010

SANUWAVE Health announces completion of patient enrollment in dermaPACE Phase III clinical trial

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, today announced that patient enrollment was completed in March in its dermaPACE™ Phase III pivotal, randomized, double-blinded, sham controlled, multicenter clinical trial comparing its Pulsed Acoustic Cellular Expression technology, utilizing the dermaPACE™ tissue regeneration device, to sham control for the treatment of diabetic foot ulcers.

6 Apr 2010

Messenger substance plays significant role in viral diseases and reactions to infections

The connection with the blood circulatory system is a significant step in the development of cancer. Within the tissue where it is growing, the tumour develops an independent existence. With signal substances it entices white blood cells from the bone marrow into the tumour tissue.

6 Apr 2010

DLVSC offers Zeltiq procedure to freeze away unwanted fat cells

Zeltiq™, an innovative technology that freezes away unwanted fat, is now available at Dermatology, Laser and Vein Specialists of the Carolinas – making DLVSC one of the first medical practices in the Southeast to offer this breakthrough in fat reduction.

6 Apr 2010

OMA calls for restrictions on the use of artificial tanning equipment

Ontario's doctors are moving to dispel the common misconception that salon tanning beds are safer than the sun. Recently, the Ontario Medical Association adopted a policy calling for restrictions on the use of artificial tanning equipment, so that tanning beds cannot be used by those under 18 years of age.

6 Apr 2010